Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55M
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
38.4M
-
Shares change
-
-225K
-
Total reported value, excl. options
-
$1.49B
-
Value change
-
-$15.7M
-
Put/Call ratio
-
1.44
-
Number of buys
-
55
-
Number of sells
-
-37
-
Price
-
$38.84
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q1 2021
127 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2021.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.4M shares
of 55M outstanding shares and own 69.81% of the company stock.
Largest 10 shareholders include ATP Life Science Ventures, L.P. (17.2M shares), RTW INVESTMENTS, LP (3.64M shares), FMR LLC (2.88M shares), Redmile Group, LLC (2.54M shares), VANGUARD GROUP INC (1.66M shares), BlackRock Inc. (1.66M shares), Cormorant Asset Management, LP (1.44M shares), GILDER GAGNON HOWE & CO LLC (1.27M shares), FEDERATED HERMES, INC. (872K shares), and STATE STREET CORP (747K shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.